Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.

ABSTRACT: Institutional review boards, which are charged with overseeing research, must classify the riskiness of proposed research according to a federal regulation known as the Common Rule (45 CFR 46, Subpart A) and by regulations governing the US Food and Drug Administration codified in 21 CFR 50. If an institutional review board determines that a clinical trial constitutes "minimal risk," there are important practical implications: the institutional review board may then allow a waiver or alteration of the informed consent process; the study may be carried out in certain vulnerable populations; or the study may be reviewed by institutional review boards using an expedited process. However, it is unclear how institutional review boards should assess the risk levels of pragmatic clinical trials. S

SUBMITTER: Lantos JD 

PROVIDER: S-EPMC4703320 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature